Question-and-Answer SessionAdam SteensbergPresident & CEO Absolutely. No, as you mentioned, it has been a very big year for us as we are, you can say, pursuing our ambition of becoming one of the key players in the growing obesity market. Really, we kicked off the year with a fantastic collaboration agreement with Roche around our main asset, petrelintide, which I'm sure we'll get to talk more about. And since then, our focus with Roche has really been to make sure that we can actually accelerate that progr ...